CCM
MRKR icon

CAAS Capital Management’s Marker Therapeutics MRKR Stock Holding History

CAAS Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,814
Closed -$108K – 1190
2021
Q1 		$108K Buy
+4,814
New +$110K ﹤0.01% 1077

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's MRKR Position: Q2 2021 in Review

CAAS Capital Management sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 4,814 shares — an estimated $108K sold.

CAAS Capital Management first reported a position in MRKR in Q1 2021 and held it in 1 quarter. The position peaked at $108K in Q1 2021. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

  • CAAS Capital Management reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 4,814 Marker Therapeutics shares in Q2 2021, an estimated $108K.
  • CAAS Capital Management first reported a position in Marker Therapeutics in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Marker Therapeutics position peaked at $108K in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.